Bluebird Bio Inc (BLUE)

[Inorout]

Great management team and great research scientists here. Some top Harvard & Tufts faculty. Expect volitility with Bluebird but it's CAR-T technology is cutting edge gene therapy. Like my last pick Kite Pharmaceuticals, I believe Bluebird is buyout candidate too. Large pharma is losing patent protection on many billion dollar drugs and gene therapy in immunology is the next new frontier in fighting cancer. If your someone who can stomach the volitility, BLUE is a good spec stock with very promising CAR-T property.